Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Rezolute (RZLT): Can Shares Reach the $10 Analyst Target for a +179% Gain?

Rezolute (RZLT): Can Shares Reach the $10 Analyst Target for a +179% Gain?

Key Takeaways

  • The central $10 stock price target is the arithmetic mean of nine current, individually verified analyst price targets, which range from $6 to $15.
  • At a latest verified price near $3.58, the stock would need to gain roughly 179% to reach $10 — a very large move that would effectively require a re-rating of the shares.
  • Every reviewed target carries a Buy or Outperform rating, but the wide $6-to-$15 range signals deep disagreement about the value of lead drug candidate ersodetug.
  • The strongest support comes from positive Phase 3 upLIFT data in tumor hyperinsulinism and an FDA recommendation for a pre-BLA meeting in congenital hyperinsulinism.
  • The biggest risks are the missed sunRIZE primary endpoint, recent share dilution from a $100 million offering, and binary regulatory outcomes.

Analyst Price Targets and Consensus View

Rezolute, Inc. (RZLT) is a late-stage rare-disease biopharmaceutical company developing ersodetug, an investigational antibody designed to treat hypoglycemia caused by hyperinsulinism. It is a stock, not an ETF. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Nine current, individually attributed analyst price targets were reviewed for this analysis: Maxim Group ($14), Citizens JMP ($15), Lake Street ($12), Guggenheim ($11), H.C. Wainwright ($10), Wedbush ($6), BTIG ($6), Craig-Hallum ($7), and JonesTrading ($6). An older Jefferies target of $20, published in December 2025, sits outside the current range and was treated as stale. The nine targets produce an arithmetic mean of roughly $9.70, which rounds to the $10 central target used throughout this article. The approximate range runs from $6 to $15.

The analyst consensus skews strongly bullish — all nine targets carry Buy or Outperform ratings — yet the dispersion is unusually wide. Lower targets near $6 reflect skepticism about the congenital hyperinsulinism (cHI) program, while targets of $12 to $15 emphasize the positive tumor hyperinsulinism (tHI) data and a potentially expanded approval opportunity. Notable recent actions include upgrades at Craig-Hallum (to Buy) and Citizens JMP (to Outperform), plus target increases at Lake Street and Citizens JMP.

Current Market Position and Path Toward the Target

Rezolute shares closed near $3.58 in mid-November 2026, leaving a required upside of approximately 179% to reach the $10 average analyst price target. By any standard, that is a very large move — consistent with a clinical-stage biotech whose valuation hinges on regulatory outcomes rather than current earnings, given the company remains unprofitable with no approved products.

The path to $10 would most plausibly run through the tHI program. Rezolute's Phase 3 upLIFT study met its primary endpoint, with 13 of 16 enrolled patients achieving the responder criterion and 12 discontinuing intravenous glucose entirely. Topline results are expected by mid-December 2026. If the final readout is clean and the FDA accepts a Biologics License Application (BLA) filing, investors could begin pricing a commercial opportunity in tHI. Meanwhile, the agency has recommended a pre-BLA meeting for ersodetug in cHI, offering a possible second regulatory path despite the sunRIZE trial's missed primary endpoint.

What Could Support a Move Toward the Target

  • Positive upLIFT data: The tHI Phase 3 study hit its primary endpoint with no drug-related safety findings, a meaningful validation of ersodetug's mechanism.
  • FDA engagement: The agency's recommendation of a Type B pre-BLA meeting for cHI keeps a second approval pathway alive.
  • Unmet medical need: Hyperinsulinism-related hypoglycemia has limited treatment options, supporting a strong commercial narrative if approved.
  • Broad pipeline optionality: Ersodetug is also being explored for hypoglycemia following gastrointestinal surgery, widening the long-term addressable market.
  • Bullish analyst revisions: Recent upgrades and target increases reflect growing confidence after the tHI readout.

What Could Prevent the Target From Being Reached

  • sunRIZE setback: The cHI Phase 3 trial missed its primary endpoint, leaving approval in that indication uncertain and dependent on the FDA's interpretation of CGM-based data.
  • Dilution: A $100 million public offering that closed in mid-November 2026 increased the share count and can pressure the stock price.
  • Binary risk: A disappointing final upLIFT readout or an FDA decision against filing would likely compress the valuation sharply.
  • Cash burn: As a pre-revenue company, Rezolute may require additional financing, creating further dilution risk.
  • Valuation gap: Even the most bullish targets assume successful regulatory execution that has not yet occurred.

Technical Levels and Market Structure

Rezolute's 52-week range spans roughly $1.07 to $11.46, underscoring the stock's extreme volatility. The $10 central target sits just below the 52-week high, meaning the shares have already traded at levels near the average analyst price target during 2026 before pulling back. Following the tHI data, the stock surged roughly 38% in a week before retreating toward $3.58 amid the equity offering, highlighting how quickly sentiment can shift in a small-cap biotech.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of about 12 months, though individual analysts may use different periods. The most important near-term catalyst is the final upLIFT topline data expected by mid-December 2026, followed by any FDA feedback on the cHI pre-BLA meeting and potential BLA submissions. Investors should also track quarterly earnings updates for cash position and dilution, analyst target revisions, and any new safety or efficacy data from the ongoing open-label extension studies.

Using AI Tools for Ongoing Monitoring

From what I see, tools like Tickeron’s AI Trend Prediction Engine can help flag shifts in sentiment around names like this one before they fully play out in the broader market. I’m watching this closely as the December data readout approaches.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RZLT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


RZLT sees its Stochastic Oscillator ascends from oversold territory

On November 18, 2026, the Stochastic Oscillator for RZLT moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 59 instances where the indicator left the oversold zone. In 55 of the 59 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on RZLT as a result. In 90 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

The Moving Average Convergence Divergence (MACD) for RZLT just turned positive on November 17, 2026. Looking at past instances where RZLT's MACD turned positive, the stock continued to rise in 48 of 50 cases over the following month. The odds of a continued upward trend are 90%.

RZLT moved above its 50-day moving average on November 18, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +18.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where RZLT advanced for three days, in 242 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RZLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for RZLT entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.727) is normal, around the industry mean (3.592). P/E Ratio (-5.173) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. RZLT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RZLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -5%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -25%. SLS experienced the highest price growth at 113%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 19%. For the same stocks of the Industry, the average monthly volume growth was -10% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
AI Patterns 1
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
275 Shoreline Drive
Phone
+1 650 206-4507
Employees
71
Web
https://www.rezolutebio.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.
CBRS fell -6.07% to $97.86 in the opening minutes of Wednesday's regular session, down from Tuesday's close of $104.18 — the move occurred during market hours, not premarket or after-hours. No verified news or fundamental catalyst found: no new filing, contract, or analyst action explains the drop, which is likely continued give-back from the post-earnings pop and the stock's habitual volatility — CBRS has averaged a ±4.5% daily swing over the past 60 sessions, and 17 of those sessions moved as much or more.
KLAR dropped -4.84% to $13.75 from Wednesday's close of $14.45, with the decline occurring during Thursday's regular session. JPMorgan downgraded the shares to Hold from Overweight and cut its price target to $17 from $20 in a note published before the open, extending a run of post-earnings target reductions.